Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 5/20 | 0.79 |
| ▸ | P2RX2 | Q9UBL9 | 5/20 | 0.79 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.77 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.76 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.71 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.71 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.71 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.69 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.68 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.66 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.66 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.66 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502130 | 1.00 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL29353873 | 1.00 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL14929510 | 1.00 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL14946389 | 1.00 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL624619 | 1.00 | P2RX3 (0.79) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL31396265 | 0.99 | P2RX3 (0.77) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL15038279 | 0.94 | P2RX3 (0.70) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL25098203 | 0.92 | P2RX3 (0.68) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL29793085 | 0.92 | P2RX3 (0.68) | P2RX3P2RX2P2RX4GPR17P2RY1 | |
| SCHEMBL31029196 | 0.92 | P2RX3 (0.86) | P2RX3P2RX2P2RX4GPR17P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275672-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-09-28 | — | — | US | disclosed |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | MODERNATX, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-9631227-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20140323354-A1 | Chemically Modified Ligase Cofactors, Donors and Acceptors | TRILINK BIOTECHNOLOGIES, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| WO-2014144979-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-8728725-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES (US) | 2014-05-20 | — | — | US | disclosed |
| US-20140038181-A1 | CHEMICALLY SUBSTITUTED THERMOSENSITIVE PROBES AND COFACTORS FOR HOT START LIGATION | TRILINK BIOTECHNOLOGIES, INC. | 2014-02-06 | — | — | US | disclosed |
| WO-2013130161-A1 | METHODS OF RESPONDING TO A BIOTHREAT | modeRNA Therapeutics (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371852-B2 | Alkyl-linked nucleotide compositions | SERENEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RX3 3314/4885P2RX2 3939/4885P2RX4 3935/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RX3 736/4885P2RX2 904/4885P2RX4 849/4885 |
| US-20170056528-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | P2RX3 736/4885P2RX2 904/4885P2RX4 849/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | P2RX3 2081/4885P2RX2 3031/4885P2RX4 3067/4885 |
| US-20160354490-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RX3 3314/4885P2RX2 3939/4885P2RX4 3935/4885 |
| US-20160354491-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | P2RX3 3314/4885P2RX2 3939/4885P2RX4 3935/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | P2RX3 2081/4885P2RX2 3031/4885P2RX4 3067/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | P2RX3 2081/4885P2RX2 3031/4885P2RX4 3067/4885 |
| US-20170252461-A1 | HETEROLOGOUS UNTRANSLATED REGIONS FOR MRNA | RNGTT, NSUN3, CPSF6 | P2RX3 3487/4885P2RX2 3712/4885P2RX4 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.